Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that paeonol-loaded liposomal gels demonstrated antioxidant effects and relieved inflammation in AD-like mice, suggesting potential benefits for treating atopic dermatitis.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

In this study, consuming a healthy, plant-based diet was associated with reduced skin inflammation and improved overall skin health, while the potential benefits of probiotics, synbiotics, and postbiotics for skin inflammation and tissue regeneration require further investigation.

This report describes a rare case of alopecia areata-like psoriasis, associated with skin lesions, following the use of dupilumab in a patient with atopic dermatitis.

In this study, Korean red ginseng was observed to improve skin hydration and reduce both the severity of atopic dermatitis and serum IgE levels after 16 weeks in patients with the condition.

This study found evidence that atopic dermatitis may increase the risk of developing rheumatoid arthritis, type 1 diabetes, and alopecia areata, but not other autoimmune diseases.

This case report describes a 42-year-old woman with atopic dermatitis, whose alopecia areata reactivated rapidly after starting dupilumab, possibly indicating an unrecognized adverse effect in AD patients.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.

This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.

This review discusses the potential role of melatonin in atopic dermatitis, focusing on its antioxidant and immunomodulatory effects, but reports no new clinical results.

This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.

This study found that patients with alopecia areata had similar total health care costs as those with atopic dermatitis, despite having fewer comorbidities and prescription medications overall.

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.

This study discusses how emerging biologics and small molecule therapies could enhance disease management and pediatric health outcomes for chronic skin conditions, suggesting their potential inclusion in treatment guidelines pending ongoing clinical trial successes.

This study found that administering dupilumab to patients with moderate-to-severe atopic dermatitis over 12 weeks altered both fungal and bacterial skin microbiomes, increasing microbial diversity and decreasing colonization by Malassezia and Staphylococcus aureus at lesion sites.

This review examines the potential of mesenchymal stem/stromal cells in treating and possibly preventing allergic diseases, and reports no new clinical results.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.

This commentary explores whether chemical exposure may contribute to the rising prevalence of atopic diseases but reports no new findings.

This review discusses the connections between atopic dermatitis and alopecia areata, emphasizing shared mechanisms and potential overlapping treatments, but it does not report new clinical findings.

This study demonstrated that allopregnanolone administration caused significant scratching in atopic dermatitis mice, and ethanol-induced scratching may be linked to increased brain allopregnanolone levels.

This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

Atopic dermatitis severity doesn't worsen during pregnancy for most women.

In this case report, a novel missense mutation c.1360G>C (p.Ala454Pro) in the MBTPS2 gene was identified in a boy with typical IFAP syndrome and severe atopic features, although no phenotype/genotype correlation was established.

This study found an association between atopic dermatitis and autoimmune diseases in both adults and children, with women more likely to experience these complications, but further research is needed due to limited participant numbers.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.